DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,208,000 | -6.3% | 21,700 | -1.6% | 0.08% | -11.0% |
| Q1 2023 | $5,555,466 | -7.4% | 22,042 | -2.5% | 0.09% | -11.7% |
| Q4 2022 | $5,998,492 | -9.0% | 22,600 | -11.4% | 0.10% | -19.5% |
| Q3 2022 | $6,591,000 | +1.7% | 25,516 | -0.2% | 0.13% | +9.4% |
| Q2 2022 | $6,481,000 | -11.0% | 25,565 | +3.0% | 0.12% | +4.5% |
| Q1 2022 | $7,280,000 | -10.7% | 24,818 | +0.1% | 0.11% | -7.4% |
| Q4 2021 | $8,155,000 | +8.8% | 24,785 | +0.7% | 0.12% | 0.0% |
| Q3 2021 | $7,495,000 | +13.8% | 24,618 | +0.3% | 0.12% | +15.2% |
| Q2 2021 | $6,586,000 | +14.2% | 24,543 | -4.2% | 0.10% | +7.1% |
| Q1 2021 | $5,768,000 | +3.4% | 25,628 | +2.0% | 0.10% | -3.9% |
| Q4 2020 | $5,579,000 | +0.5% | 25,115 | -2.5% | 0.10% | -8.1% |
| Q3 2020 | $5,549,000 | +22.3% | 25,769 | +0.4% | 0.11% | +13.3% |
| Q2 2020 | $4,538,000 | +19.6% | 25,665 | -6.4% | 0.10% | +6.5% |
| Q1 2020 | $3,795,000 | -14.6% | 27,422 | -5.3% | 0.09% | +12.2% |
| Q4 2019 | $4,445,000 | -1.7% | 28,959 | -7.5% | 0.08% | -6.8% |
| Q3 2019 | $4,520,000 | +1.6% | 31,296 | +0.6% | 0.09% | 0.0% |
| Q2 2019 | $4,448,000 | +5.2% | 31,120 | -2.8% | 0.09% | +3.5% |
| Q1 2019 | $4,227,000 | +27.5% | 32,017 | -0.4% | 0.08% | +11.8% |
| Q4 2018 | $3,314,000 | -8.1% | 32,137 | -3.2% | 0.08% | +4.1% |
| Q3 2018 | $3,606,000 | +8.8% | 33,183 | -1.2% | 0.07% | +4.3% |
| Q2 2018 | $3,315,000 | -12.3% | 33,589 | -12.9% | 0.07% | -13.6% |
| Q1 2018 | $3,778,000 | +0.4% | 38,585 | -4.8% | 0.08% | +6.6% |
| Q4 2017 | $3,762,000 | +9.5% | 40,531 | +1.2% | 0.08% | +5.6% |
| Q3 2017 | $3,437,000 | +0.6% | 40,063 | -1.0% | 0.07% | -7.7% |
| Q2 2017 | $3,417,000 | +26.5% | 40,486 | +28.2% | 0.08% | +21.9% |
| Q1 2017 | $2,701,000 | +9.7% | 31,574 | -0.2% | 0.06% | +6.7% |
| Q4 2016 | $2,463,000 | +2.2% | 31,647 | +2.9% | 0.06% | 0.0% |
| Q3 2016 | $2,411,000 | -10.9% | 30,751 | +14.8% | 0.06% | -13.0% |
| Q2 2016 | $2,706,000 | +7.3% | 26,796 | +0.8% | 0.07% | +4.5% |
| Q1 2016 | $2,521,000 | -4.8% | 26,580 | -6.7% | 0.07% | -8.3% |
| Q4 2015 | $2,647,000 | +19.9% | 28,499 | +10.0% | 0.07% | +10.8% |
| Q3 2015 | $2,208,000 | +1.8% | 25,915 | +2.3% | 0.06% | +10.2% |
| Q2 2015 | $2,169,000 | -26.0% | 25,342 | -26.6% | 0.06% | -3.3% |
| Q1 2015 | $2,930,000 | -5.2% | 34,515 | -4.3% | 0.06% | -4.7% |
| Q4 2014 | $3,092,000 | +11.3% | 36,079 | -1.3% | 0.06% | +8.5% |
| Q3 2014 | $2,777,000 | -8.2% | 36,549 | -4.9% | 0.06% | -6.3% |
| Q2 2014 | $3,025,000 | +11.3% | 38,425 | +6.0% | 0.06% | +6.8% |
| Q1 2014 | $2,718,000 | +1.6% | 36,246 | +4.6% | 0.06% | 0.0% |
| Q4 2013 | $2,676,000 | +11.9% | 34,663 | +0.5% | 0.06% | +5.4% |
| Q3 2013 | $2,391,000 | -49.1% | 34,495 | -53.5% | 0.06% | -50.4% |
| Q2 2013 | $4,696,000 | +4.3% | 74,193 | +2.4% | 0.11% | 0.0% |
| Q1 2013 | $4,504,000 | +12.0% | 72,469 | +0.7% | 0.11% | -0.9% |
| Q4 2012 | $4,023,000 | – | 71,965 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |